NEWARK, Calif., March 2, 2020 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (Nasdaq:PTGX) will announce fourth quarter and
year end 2019 financial results after the NASDAQ market closes on
Tuesday, March 10, 2020. Protagonist
management will host a year end update call at 4:30 p.m. EDT/1:30 p.m.
PDT the same day.
Conference Call and Webcast Information
Protagonist executives will host a conference call at
4:30 p.m. EDT/1:30 p.m. PDT on Tuesday, March 10, 2020. To
access the live call, dial 1-844-515-9178 (U.S./Canada) or 1-614-999-9313 (international) and
refer to conference ID number 5591627. A live and archived webcast
of the call will also be accessible in the Investors section of the
Company's website at www.protagonist-inc.com. A replay will be
available on the company's website approximately two hours after
the call and will remain available for 60 days.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical
company that utilizes a proprietary technology platform to discover
and develop novel peptide-based drugs to address significant unmet
medical needs and transform existing treatment paradigms for
patients. The Company currently has three different assets in
various stages of clinical development, and these were discovered
internally through the use of its peptide technology platform.
PTG-300 is an injectable hepcidin mimetic in development for the
potential treatment of iron overload and related blood disorders,
including hereditary hemochromatosis and rare diseases such as
beta-thalassemia and polycythemia vera. PTG-200 is an orally
delivered, gut-restricted interleukin-23 receptor specific
antagonist peptide in Phase 2 clinical development for the
potential treatment of inflammatory bowel disease, with Crohn's
disease as the initial indication. The Company has a worldwide
license and collaboration agreement with Janssen Biotech, Inc., for
the clinical development of PTG-200. PN-943 is an orally delivered,
gut-restricted alpha-4-beta-7 integrin specific antagonist peptide
in clinical development for the potential treatment of inflammatory
bowel disease, with a Phase 2 ulcerative colitis study expected to
commence in the second quarter of 2020. Protagonist is
headquartered in Newark,
California. For further information, please visit
www.protagonist-inc.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements
include statements regarding our intentions or current expectations
concerning, among other things, the potential for our clinical
programs, the initiation and availability of results of our
clinical trials and the sufficiency of our financial resources, the
Company's ability to fund its clinical trials, the initiation of
and enrollment of patients in the Company's clinical trials, the
results of clinical trials and the outlook for our other programs.
In some cases, you can identify these statements by forward-looking
words such as "will," "expect," "potential," or the negative or
plural of these words or similar expressions. Forward-looking
statements are not guarantees of future performance and are subject
to risks and uncertainties that could cause actual results and
events to differ materially from those anticipated, including, but
not limited to, our ability to develop and commercialize our
product candidates, our ability to earn milestone payments under
our collaboration agreement with Janssen, our ability to use and
expand our programs to build a pipeline of product candidates, and
our ability to obtain and maintain regulatory approval of our
product candidates. Additional information concerning these and
other risk factors affecting our business can be found in our
periodic filings with the Securities and Exchange Commission,
including under the heading "Risk Factors" contained in our Annual
Report on Form 10-K for the year ended December 31, 2019, filed with the Securities and
Exchange Commission. Forward-looking statements are not guarantees
of future performance, and our actual results of operations,
financial condition and liquidity, and the development of the
industry in which we operate, may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. We assume no obligation
to update our forward-looking statements, whether as a result of
new information, future events or otherwise, after the date of this
press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-announce-fourth-quarter-and-full-year-2019-financial-results-301014641.html
SOURCE Protagonist Therapeutics, Inc.